• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form F-6EF filed by I-MAB

    8/1/25 6:01:09 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    F-6EF 1 e664752_f6ef-imab.htm

     

    As filed with the Securities and Exchange Commission on August 1, 2025 Registration No. 333 –

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________________________

     

    FORM F-6

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

    AMERICAN DEPOSITARY RECEIPTS

    _____________

     

    I-Mab

    (Exact name of issuer of deposited securities as specified in its charter)

    _____________

     

    N/A

    (Translation of issuer’s name into English)

    _____________

     

    Cayman Islands

    (Jurisdiction of incorporation or organization of issuer)

    _________________________________

     

    CITIBANK, N.A.

    (Exact name of depositary as specified in its charter)

    _____________

     

    388 Greenwich Street

    New York, New York 10013

    (877) 248-4237

    (Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

    _____________

     

    Joseph Skelton

    Chief Financial Officer

    2440 Research Boulevard, Suite 400

    Rockville, MD 20850

    (240) 745-6330

    (Address, including zip code, and telephone number, including area code, of agent for service)

    _________________________________

     

    Copies to:

     

    Christian Plaza, Esq.

    Mark Ballantyne, Esq.

    Cooley LLP

    11951 Freedom Drive

    Reston, VA 20190-5640

    (703) 456-8000

    Herman H. Raspé, Esq.

    Jean-Claude Lanza, Esq.

    Patterson Belknap Webb & Tyler LLP
    1133 Avenue of the Americas
    New York, New York 10036
    (212) 336-2000

    _________________________________

     

    It is proposed that this filing become effective under Rule 466: ☒  immediately upon filing.
       
      ☐  on (Date) at (Time).
       
    If a separate registration statement has been filed to register the deposited shares, check the following box:  ☐

     _________________________________

     

    CALCULATION OF REGISTRATION FEE

     

    Title of Each Class of
    Securities to be Registered
    Amount to be
    Registered

    Proposed Maximum

    Aggregate Price Per Unit*

    Proposed Maximum

    Aggregate Offering Price**

    Amount of

    Registration Fee

    American Depositary Shares (“ADSs”), each ten (10) ADSs representing the right to receive twenty-three (23) ordinary shares of a par value of US$0.0001 each of I-Mab (the “Company”) 100,000,000 ADSs $5.00 $5,000,000.00 $765.50
     

    *     Each unit represents 100 ADSs.

    **   Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.

     

      

     

     

     

     

    This Registration Statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

     

     

    ii

     

     

    PART I

     

    INFORMATION REQUIRED IN PROSPECTUS

     

    Cross Reference Sheet

     

    Item 1.DESCRIPTION OF SECURITIES TO BE REGISTERED

     

     

    Item Number and Caption

     

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

     

    1. Name of Depositary and address of its principal executive office   Face of Receipt -  Introductory Article.
           
    2. Title of Receipts and identity of deposited securities   Face of Receipt  - Top Center.
             
    Terms of Deposit:    
         
      (i) The amount of deposited securities represented by one American Depositary Share (“ADSs”)   Face of Receipt  - Upper right corner.
             
      (ii) The procedure for voting, if any, the deposited securities   Reverse of Receipt  - Paragraphs (17)
    and (18).
             
      (iii) The collection and distribution of dividends   Reverse of Receipt - Paragraph (15).
             
      (iv) The transmission of notices, reports and proxy soliciting material   Face of Receipt  - Paragraph (14);
    Reverse of Receipt - Paragraph (18).
             
      (v) The sale or exercise of rights  

    Reverse of Receipt – Paragraphs (15)

    and (17).

             
      (vi) The deposit or sale of securities resulting from dividends, splits or plans of reorganization  

    Face of Receipt - Paragraphs (3) and (6);

    Reverse of Receipt - Paragraphs (15) and (17).

             
      (vii) Amendment, extension or termination of the deposit agreement   Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).
             
      (viii) Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs   Face of Receipt - Paragraph (14).
             
      (ix) Restrictions upon the right to deposit or withdraw the underlying securities   Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (9) and (10).

      

    I-1 

     

     

     

     

    Item Number and Caption 

     

    Location in Form of American

    Depositary Receipt (“Receipt”)
    Filed Herewith as Prospectus

             

      (x) Limitation upon the liability of the Depositary  

    Face of Receipt - Paragraph (8);

    Reverse of Receipt - Paragraphs (20) and (21).

             
    3.     Fees and charges which may be imposed directly or indirectly on holders of ADSs   Face of Receipt - Paragraph (11).
             
    Item 2.  AVAILABLE INFORMATION   Face of Receipt - Paragraph (13).

     

    The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

      

    I-2 

     

     

     

    PROSPECTUS

     

    The Prospectus consists of the form of American Depositary Receipt included as Exhibit A to the Deposit Agreement filed as Exhibit (a) to this Registration Statement on Form F-6 and is incorporated herein by reference.

     

     

    I-3 

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 3.EXHIBITS

     

    (a)Deposit Agreement, dated as of January 22, 2020, by and among I-Mab (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (the “Deposit Agreement”). ___ Filed herewith as Exhibit (a).

     

    (b)Any other agreement to which the Depositary is a party relating to the issuance of the American Depositary Shares registered hereunder or the custody of the deposited securities represented thereby. ___ None.

     

    (c)Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ___ None.

     

    (d)Opinion of counsel for the Depositary as to the legality of the securities to be registered. ___ Filed herewith as Exhibit (d).

     

    (e)Certificate under Rule 466. ___ Filed herewith as Exhibit (e).

     

    (f)Powers of Attorney for certain officers and directors and the authorized representative of the Company. ___ Set forth on the signature pages hereto.

      

    II-1 

     

     

    Item 4.UNDERTAKINGS

     

    (a)The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

     

    (b)If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

      

    II-2 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, by and among I-Mab, Citibank, N.A., as depositary, and all Holders and Beneficial Owners from time to time of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 1st day of August, 2025.

      

     

    Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each ten (10) American Depositary Shares representing the right to receive twenty-three (23) ordinary shares of I-Mab

     

    CITIBANK, N.A., solely in its capacity as Depositary

         
      By:   /s/ Leslie DeLuca
        Name:  Leslie DeLuca
        Title:    Attorney-in-Fact

     

    II-3 

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, I-Mab certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Rockville, Maryland, on August 1, 2025.

      

     

    I-Mab  

         
      By:   /s/ Joseph Skelton
          Name: Joseph Skelton
        Title: Chief Financial Officer

     

    II-4 

     

     

    POWERS OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Sean Fu and Joseph Skelton to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form F-6 has been signed by the following persons in the following capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Sean Fu   Chief Executive Officer and Director (Principal   August 1, 2025
    Sean Fu   Executive Officer)    
             
    /s/ Joseph Skelton   Chief Financial Officer (Principal Financial Officer   August 1, 2025
    Joseph Skelton   and Principal Accounting Officer)    
             
    /s/ Wei Fu   Director   August 1, 2025
    Wei Fu        
             
    /s/ Lielie Zhang   Director   August 1, 2025
    Lielie Zhang        
             
    /s/ Chun Kwok Alan Au   Director   August 1, 2025
    Chun Kwok Alan Au        
             
    /s/ Conor Chia-hung Yang   Director   August 1, 2025
    Conor Chia-hung Yang        
             
    /s/ Sean Cao   Director   August 1, 2025
    Sean Cao        

     

     

      

    II-5 

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of I-Mab, has signed this Registration Statement on Form F-6 in Rockville, Maryland, on August 1, 2025.

     

      I-Mab Biopharma US Ltd.
       
     

    Authorized Representative in the U.S.

         
      By: /s/ Joseph Skelton
     

    Name: Joseph Skelton

    Title: Chief Financial Officer

     

    II-6 

     

      

    Index to Exhibits

      

    Exhibit Document

    Sequentially

    Numbered Page

         
    (a) Deposit Agreement  
         
    (d) Opinion of counsel to the Depositary  
         
    (e) Rule 466 Certification  

     

     

     

    II-7

     

     

     

     

     

    Get the next $IMAB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Siebert Williams Shank initiated coverage on I-Mab with a new price target

    Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

    12/9/21 8:33:47 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on I-MAB with a new price target

    Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

    11/1/21 4:39:06 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

    HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

    9/1/21 6:14:32 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    SEC Filings

    View All

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/11/25 7:06:07 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by I-MAB

    424B5 - I-Mab (0001778016) (Filer)

    8/4/25 7:30:26 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by I-MAB

    6-K - I-Mab (0001778016) (Filer)

    8/4/25 7:00:15 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers

    Enrollment in the planned second dose expansion cohort completed ahead of expectationsTopline results expected in Q1 2026 Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, Md., Aug. 11, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that enrollment in the planned Phase 1b dose expansion cohorts evaluating givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in combination with nivolumab and mFOLFOX6, has been completed ahead of expectations. The Phase 1b study (NCT04900818) is evaluating the

    8/11/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Everest Medicines Expands Strategic Investment in I-MAB

    - Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall response rate (ORR) of 83% in combination with immunotherapy in a Phase 1b trial of first line gastric cancers. - I-Mab's differentiated 4-1BB receptor targeting platform and bispecific antibody pipeline are highly complementary with the Company's existing mRNA cancer vaccines and in vivo CAR-T platform. - Complementary and synergistic clinical development and business development platforms, especially I-

    8/1/25 8:56:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares

    ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United States of 33,333,334 American Depositary Shares (ADSs) representing 76,666,668 ordinary shares at an offering price of $1.95 per ADS, for total gross proceeds of approximately $65 million. All of the ADSs to be sold in the offering will be offered by I-Mab. The offering is expected to close on August 5, 2025, subject to customary closing conditions. The offering included participation from new and existing in

    8/1/25 8:00:28 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

    Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

    4/3/25 4:01:00 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

    Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

    1/6/25 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports Third Quarter 2024 Results

    Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

    11/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/13/24 11:26:50 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by I-MAB (Amendment)

    SC 13G/A - I-Mab (0001778016) (Subject)

    2/9/24 4:01:20 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by I-MAB

    SC 13D - I-Mab (0001778016) (Subject)

    12/1/23 2:41:06 PM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IMAB
    Financials

    Live finance-specific insights

    View All

    I-Mab to Release Q3 2024 Financial Results on November 14, 2024

    ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

    10/31/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

    Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

    8/28/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    I-Mab to Release 1H 2024 Financial Results on August 28, 2024

    Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

    8/14/24 7:00:00 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care